Denver Nephrologists, P.C.   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Denver CO United States

Organization Overview

First Clinical Trial
2009
NCT00785629
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Denver Nephrologists, PC | Denver Nephrologists, P.C. | Geoffrey Block

Active Ingredients

Drugs in Phase 3 Trials (3)

epoetin (Epogen) (1 trial)

ferric citrate (AURYXIA) (1 trial)

roxadustat (1 trial)

Drugs in Phase 1 Trials (1)

gcs-100 (1 trial)

Drugs in Other Trials (5)

agalsidase alfa (Replagal) (1 trial)

calcium (1 trial)

chitosan (1 trial)

lanthanum (2 trials)

sevelamer (renagel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Hyperphosphatemia (Phase 3)

Kidney Diseases (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 9